Table 1.
Demographic data of two parts of studies
| Control group | Flumazenil group | |||
|---|---|---|---|---|
|
|
|
|||
| Part of studies | Part 1 | Part 2 | Part 1 | Part 2 |
| Number of patients | 24 | 30 | 25 | 30 |
| Gender (Female/Male) | 14/10 | 12/18 | 12/13 | 11/19 |
| Age (y) | 26 ± 3.6 | 43 ± 7.5 | 25 ± 4 | 44 ± 10.7 |
| Index of body (kg/m2) | 22.7 ± 6.4 | 21.02 ± 2.12 | 22.1 ± 2.08 | 22.00 ± 2.22 |
| Basic Hb (g/L) | 139.6 ± 19.8 | 129.0 ± 16.5 | 131.1 ± 15.5 | 126.8 ± 13.1 |
| Basic ALT (IU/L) | 22.2 ± 16.5 | 26.1 ± 10.4 | 21.5 ± 8.5 | 22.1 ± 4.2 |
| Basic creatine (mmol/L) | 71.8 ± 19.3 | 59.7 ± 9.3 | 62.4 ± 16.9 | 60.7 ± 18.1 |
| Basic BIS | 95.7 ± 3.6 | 95.1 ± 3.9 | 95.4 ± 3.0 | 95.0 ± 3.3 |
| BIS at loss of consciousness | 82.1 ± 22.4 | 87.9 ± 12.7 | 87.8 ± 11.3 | 82.0 ± 22.0 |
| ETSevo at loss of consciousness (%) | 5.1 ± 1.6 | 4.3 ± 1.6 | 4.6 ± 1.4 | 3.9 ± 0.8 |
| Time to loss of consciousness during induction (s) | 78.0 ± 33.6 | 80.1 ± 22.5 | 73.8 ± 25.8 | 76.4 ± 28.2 |